You are here: Industry Insights > Products Guide > Urgent Sourcing Needs of【en-CPhI.cn】2018.05.02

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Riociguat(625115-55-1)

Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate

2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)

4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-

1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)

1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

Urgent Sourcing Needs of【en-CPhI.cn】2018.05.02

en-cphi.cnMay 02, 2018

Tag: en-CPhI.cn , urgent , Sourcing Needs

Favorites

【CPhI.cn】provides the free-of-charge One-to-One Matching Service every week. Your dedicated client service officer collects your sourcing needs and searches suitable suppliers for you to improve your sourcing efficiency greatly.

The validity of the sourcing needs lasts one week.

If your company could provide the following products like API active product ingredient, you can email the product name to Miki. She will reply you with the detailed information including the buyers' contact information.

Contact Person: Miki

Email: Miki.Zhou@ubmsinoexpo.com

Tel: 86-21-33392254

Name of the Product	CAS No.	Quantity	Terms	Payment	Details	Date	Country
JINTROPIN 100IU genescience pharmaceuticals co. ltd. (gensci)		5 KITS		WESTERN UNION		43209.73056	DEUTSCHLAND
NEOMYCINE SULFATE USP	1405-10-3	10/50/100/500 kg	ASAP	LC/CAD/	API GRADE WITH REGULATORY SUPPORT	43210.40069	ALGERIA
Hesperidin methyl chalcone	24292-52-2	10/50/350 KG	ASAP	LC/CAD/	API GRADE WITH REGULATORY SUPPORT	43210.40069	ALGERIA
Chlorothymol EP	15686-33-6	25 kg validation 250 / 750 kg	ASAP	LC/CAD/	GMP CTD DMF REGULATORY SUPPORT REQUIRED	43210.40069	ALGERIA
Benoxinate		50 gm	4mg/ml USP		So, pls., advise us with your final rock bottom price for it based on CIF AIR CAIRO, Egypt. Also, pls., send us a valid GMP, COA USP for it & inform us with packing details & delivery time. Also, accept the payment term to be CAD or LC at sight.	43212	Egypt
azidiol	94241-98-2				Quantity:10ltr；Quality Standards:preservative for milk samples；Packing:1 ltr	43207.74652	Serbia

Previous:MRC awards Bristol researcher £1.2M to investigate immune defence against microbes

Next:Attacking treatment-resistant prostate cancer by blocking its stress response

Research and Application of Artemisia Argyi

XiaonishaAugust 12, 2024

Mugwort, also known as fragrant mugwort or Artemisia argyi, is a herbaceous plant belonging to the Compositae family.

Research Progress on the Application of Biologics in Pediatric Asthma

XiaomichongJuly 19, 2024

Research Progress on the Pharmacological Effects and New Drug Forms of Artemisinin and Its Derivatives

XiaomichongJuly 19, 2024

Urgent Sourcing Needs of【en-CPhI.cn】2018.05.02 | Pharmasources.com

Research and Development Status and Progress of Antibody Technology (Part Ⅱ)

XiaomichongJuly 18, 2024

Antibody-based biological therapeutic drugs have been playing an increasingly important role in biopharmaceuticals due to their strong targeting, good specificity, and significant therapeutic effects.

Urgent Sourcing Needs of【en-CPhI.cn】2018.05.02

Related News

Research and Application of Artemisia Argyi

Research Progress on the Application of Biologics in Pediatric Asthma

Research Progress on the Pharmacological Effects and New Drug Forms of Artemisinin and Its Derivatives

Research and Development Status and Progress of Antibody Technology (Part Ⅱ)

You may like
More>>

Urgent Sourcing Needs of【en-CPhI.cn】2018.05.02

Related News

Research and Application of Artemisia Argyi

Research Progress on the Application of Biologics in Pediatric Asthma

Research Progress on the Pharmacological Effects and New Drug Forms of Artemisinin and Its Derivatives

Research and Development Status and Progress of Antibody Technology (Part Ⅱ)

You may likeMore>>

You may like
More>>